Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients.
about
Risk factors for osteoporosis in inflammatory bowel disease patientsEffects of anti-tumor necrosis factor α agents on boneManagement of endocrine disease: Secondary osteoporosis: pathophysiology and managementEvaluation and management of the premenopausal woman with low BMD.Pathological fractures in paediatric patients with inflammatory bowel disease.Growth and bone health in paediatric patients with Crohn's disease receiving subcutaneous tumor necrosis factor antibody.Bone Mineral Density, Bone Turnover, and Systemic Inflammation in Non-cirrhotics with Chronic Hepatitis CInitiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseasesOsteoporosis and inflammation.Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease.Osteoporosis in young adults: pathophysiology, diagnosis, and management.Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease.Adalimumab Therapy Has a Beneficial Effect on Bone Metabolism in Patients with Crohn's Disease.Premenopausal Osteoporosis.Bone mineral density and inflammatory bowel disease severity.Risk factors for osteoporosis in Crohn's disease: infliximab, corticosteroids, body mass index, and age of onset.Metabolic Bone Disease in Gastrointestinal Disorders
P2860
Q26776142-5392E741-3214-4012-B33B-56C79C845012Q26851274-25EBD40B-D67A-466C-8D8B-ED315718D87DQ26998249-B2F63A0D-AA07-4328-B075-0A8204574CD5Q34069654-6E0B18B2-A428-4900-B542-5A552E523A22Q34378165-9AA7527F-983E-45DA-95D4-4CEAD38B7838Q35692293-750E0AEB-4BBF-4A1E-A149-CC7443794ED3Q36702302-B77202EB-ED91-4DE9-8B3D-8BA37BFB8340Q36781280-BDB92DA3-32E1-4A13-93EC-4BD02AA0828BQ37756576-54ED2997-086F-4E3C-85FE-EE51AAF5BBC0Q37869193-5EA72B47-1D1D-4263-8314-24A4DE01D859Q38017609-987D77BE-BDF5-40DC-A787-2359BAE12BD8Q38041419-25FFC510-58D4-4D3C-B4C6-D4E078B14A4AQ38904535-5D9E0027-2637-4450-8EE0-0B8D2C6B0E95Q39107524-57F693A4-7A80-4BCE-84A8-9F57B8702072Q42664538-682BD509-38AC-4ED4-A3CF-501A41F5E5DBQ46959285-D8849BD3-3509-4ED6-9AFD-950F659BB593Q57169423-6CE62741-E01F-467D-B1F5-AC8FE3A6F4A6
P2860
Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients.
@ast
Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients.
@en
Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients.
@nl
type
label
Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients.
@ast
Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients.
@en
Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients.
@nl
prefLabel
Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients.
@ast
Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients.
@en
Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients.
@nl
P2093
P2860
P356
P1476
Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients.
@en
P2093
David Armstrong
Marina Mauro
Vladimir Radovic
P2860
P304
P356
10.1155/2007/216162
P407
P577
2007-10-01T00:00:00Z